Menu
Recruiting NCT06978699

A Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Phase II Interventional PNH - Paroxysmal Nocturnal Hemoglobinuria

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: XH-S003 Capsule.
Who it may be relevant to
Registry conditions: PNH - Paroxysmal Nocturnal Hemoglobinuria. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
China
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

A Multicenter, Randomized, Single-blind Phase II Study Evaluating the Efficacy and Safety of XH-S003 Capsules in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Overview

This is a multicenter, randomized, single-blind Phase II trial to evaluate the efficacy and safety of XH-S003 capsules in PNH patients. About 24 PNH patients will be enrolled and randomized to three dose levels and take XH-S003 capsules orally

Interventions

  • Drug XH-S003 Capsule
    25mg \& 100mg

Primary outcome measures

  • Changes of hemoglobin compared with baseline [Time frame: 8 weeks]
Secondary outcome measures (5)
  • Proportion of subjects with an increase in Hb ≥20g/L compared with baseline (without RBC transfusion); [Time frame: 8 weeks]
  • Changes in Indirect Bilirubin compared to baseline; [Time frame: 8 weeks]
  • Changes in reticulocyte counts compared to baseline; [Time frame: 8 weeks]
  • Proportion of subjects without RBC transfusion [Time frame: 8 weeks]
  • Changes in LDH compared with baseline [Time frame: 8 weeks]

Eligibility criteria

Inclusion criteria

  • Male or female with aged ≥18 years old;
  • Weight ≥40 kg and BMI≥18 kg/m2 ;
  • Diagnosed with PNH: with red blood cell or granulocyte clone levels >10% detected by flow cytopy within 6 months prior to screening or during screening;
  • Patients who have not previously received any complement inhibitor therayp;
  • LDH > 1.5×ULN detected two times during the screening period (interval of 2 to 8 weeks);
  • Hb meets one of the following conditions: (1) Hb <100 g/L at the first screening visit, and subjects receive RBC transfusion because of PNH-related anemia during the screening period; (2) The average Hb of two tests during the screening period <100 g/L (interval of 2\~8 weeks);
  • Vaccination against Neisseria meningitidis and Streptococcus pneumoniae before the first administration. If the subject has not been vaccinated previously or requires booster vaccination (according to local vaccination policies), vaccination must be administered at least 2 weeks before the first administration. If the first administration must begin less than 2 weeks after vaccination, preventive antibiotic treatment must begin at least 2 weeks after vaccination;

Exclusion criteria

  • Subjects with laboratory evidence of bone marrow failure during the screening period (reticulocyte count <100×109/L, platelet count <30×109/L, or neutrophil count <0.5×109/L);
  • Subjects receiving other therapies prior to screening who have not achieved the following treatment durations:
  • Erythropoietin or immunosuppressants for at least 8 weeks; • Systemic corticosteroids for at least 4 weeks; • Iron supplements, vitamin B12, or folic acid for at least 4 weeks; • Anticoagulants: Vitamin K antagonists for at least 4 weeks with stable international normalized ratio (INR) (as determined by the investigator), low molecular weight heparin for at least 4 weeks; • Hypoxic-inducing factor prolyl hydroxylase inhibitors (HIF-PHI) for at least 8 weeks; • Androgens for at least 4 weeks;
  • A history of bone marrow/hematopoietic stem cell or solid organ transplantation;
  • Alanine aminotransferase (ALT), γ-glutamyl transpeptidase (GGT), or alkaline phosphatase (ALP) >3×ULN at screening; - Positive HIV antibody, active syphilis infection, positive HBsAg, active HCV infection, or active tuberculosis infection at screening;
  • Known or suspected immunodeficiency diseases or hereditary complement deficiency at screening;
  • A history of Neisseria meningitidis infection;
  • Subjects with chronic active or recurrent infections within 1 year prior to screening;
  • Subjects with systemic active bacterial, viral (including COVID-19), or fungal infections within 2 weeks prior to the first administration; subjects with body temperature >38°C within 7 days prior to the first administration;

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

China · 1 center
  • TianJin Medical University General Hospital — Tianjin

Identifiers

NCT: NCT06978699 · XH-S003-II-101

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗